Pipelines that reproduce
Workflows that give the same answer after the person who wrote them has left. Tool versions, parameters and intermediates are recorded, so the numbers can be regenerated months later.
From raw sequencing reads to the figure in your paper, we find the point where the work actually stalls and fix that part. We look at the problem, not at what we could sell you.
Every lab gets stuck somewhere different. These four come up most.
Workflows that give the same answer after the person who wrote them has left. Tool versions, parameters and intermediates are recorded, so the numbers can be regenerated months later.
Statistics and machine learning to narrow candidates, written up so you can say why each one survived. Validation design is part of the conversation.
Omics, clinical and imaging data joined into one cohort. Standardisation rules and missing-data handling are documented, so whoever joins later makes the same calls.
A design loop from target structure to candidate sequences. We do not take predicted scores at face value; we agree with you on what has to be checked at the bench.
Not with a large contract. Small first, wider once it proves useful.
An hour or two of conversation. The problem is usually not the method but the handoffs around it.
The most painful part first, before designing the whole. Typically two to four weeks.
Not an example set. This is where most of the assumptions get corrected.
If it earns its place, it gets wired into your environment. If not, we stop there — that is also a result.
Design and build for WGS, WES, RNA-seq, scRNA-seq and related data types.
An outside read of the methods and interpretation behind work you have already run.
Scattered data brought into an analysable shape, with the rules written down.
Choosing and validating predictive or in-silico models against your actual question.
Turning numbers into sentences and figures that can go into a paper or a report.
Setting up AURORA, BioWrit or PepDesigner to fit how your group works.
Making sure your team can run what was built without us.
University and hospital labs, research groups inside biotech companies, and small teams that cannot justify a full-time analyst. The most common starting point is a group with data piling up and no clear next step.
Yes, and it is usually better. Most analysis problems are decided at the experimental design stage.
A first narrow deliverable is typically two to four weeks. Full pipeline work depends on scope, which we set together after the first conversation.
No. Work can be set up to run inside your environment, and we default to that because clinical data usually cannot be exported.
You do. Code and documentation are handed over so your team can run it.
Specific ones. "This analysis gives a different answer depending on who runs it" resolves far faster than "we want to adopt AI".
Send us a paragraph on what is stuck. If it is not a fit, we will say so.